Detection of 1-benzylpiperazine and 1-(3-trifluoromethylphenyl)-piperazine in urine analysis specimens using GC-MS and LC-ESI-MS

Journal of Analytical Toxicology

Volumn 32, Issue 6, 2008, Pages 444-450

  Vorce, Shawn P ^a   Holler, Justin M ^a   Levine, Barry ^a   Past, Marilyn R ^a  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 1 BENZYLPIPERAZINE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG SCREENING; ELECTROSPRAY MASS SPECTROMETRY; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; HUMAN; ION MONITORING; KIDNEY CONCENTRATING CAPACITY; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; URINALYSIS;

EID: 48249142826     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/32.6.444     Document Type: Article

References (40)

1. U.S. Drug Enforcement Administration. Ecstasy combination tablet (containing methamphetamine, BZP, TFMPP, MDMA, dibenzylpiperazine, and procaine) in Concord, California. Microgram Bull. 41(1): 1 (2008).
2. U.S. Drug Enforcement Administration. Ecstasy mimic tablet (containing benzylpiperzine (BZP), methamphetamine, and caffeine) in Sikeston, Missouri. Microgram Bull. 40(10): 91-92 (2007).
3. U.S. Drug Enforcement Administration. "Flying Star" and "Red Dragon" tablets (containing benzylpiperazine (BZP) and trifluoromethylphenlypiperazine (TFMPP)) in commercial-style packaging in Singapore. Microgram Bull. 40(9): 87 (2007).
4. U.S. Drug Enforcement Administration. Ecstasy mimic tablets (containing 1 -(3-chlorophenyl)-piperazine (mCPP)) in Hammond, Indiana. Microgram Bull. 40(4): 39 (2007).
5. U.S. Drug Enforcement Administration. Ecstasy combination tablets (containing MDMA, and 3-chlorophenylpiperazine (mCPP)) in Thessaloniki, Greece. Microgram Bull. 39(12): 147 (2006).
6. U.S. Drug Enforcement Administration. Ecstasy mimic tablets containing 1 -(3-chlorophenyl)-piperazine (mCPP) in Vernon Hills, Illinois. Microgram Bull. 39(10): 123 (2006).
7. U.S. Drug Enforcement Administration. Ecstasy mimic tablets (containing meta-chlorophenyl-piperazine (MCPP)), and capsules containing 2,5-dimethoxy-4-iodophenethylamine (2C-I), in Iowa. Microgram Bull. 39(9): 112 (2006).
8. U.S. Drug Enforcement Administration. Ecstasy mimic tablets (containing meta-chlorophenyl-piperazine (mCPP)) in Frisco, Texas. Microgram Bull. 39(9): 112-113 (2006).
9. U.S. Drug Enforcement Administration. Ecstasy mimic tablets (containing meta-chlorophenyl-piperazine (mCPP)) in the Balearic Islands. Microgram Bull. 39(5): 56 (2006).
10. U.S. Drug Enforcement Administration. N-Benzylpiperazine (BZP) and 3-trifluoromethyphenyl-piperazine (TMFPP) laboratory in Houston, Texas. Microgram Bull. 39(4): 45 (2006).
11. U.S. Drug Enforcement Administration. Ecstasy mimic tablets (containing 1 -(4-chlorophenyl)-piperazine (cPP)) in Naples, Italy. Microgram Bull. 39(2): 18 (2006).
12. U.S. Drug Enforcement Administration. Benzylpiperazine (BZP) and N-(3-trifluoromethylphenyl)-piperazine (TFMPP). Microgram 34:23(2001).
13. U.S. Drug Enforcement Administration. BZP and Nexus tablets. Microgram 34: 3 (2001).
14. U.S. Drug Enforcement Administration. Piperazines in Roanoke, Virginia. Microgram 34: 43 (2001).
15. U.S. Drug Enforcement Administration. Benzylpiperazine and peyote. Microgram 34: 65 (2001).
16. U.S. Drug Enforcement Administration. Seven unusual tablet submissions in Largo, Florida. Microgram 34: 157 (2001).
17. U.S. Drug Enforcement Administration. 1 -Benzylpiperazine (BZP) and N-(3-trifluoromethylphenyl)piperazine (TFMPP). Microgram 34:225(2001).
18. U.S. Drug Enforcement Administration. Benzylpiperazine (BZP) and N-(3-trifluoromethylphenyl)piperazine (TFMPP). Microgram 34:196(2001).
19. J. Sheridan, R. Butler, C. Wilkins, and B. Russell. Legal piperazine-containing party pills-a new trend in substance misuse. Drug Alcohol Rev. 26: 335-343 (2007).
20. D. de Boer, I.J. Bosman, E. Hidvegi, C. Manzoni, A.A. Benko, R.L. Dos, and R.A. Maes. Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market. Forensic Sci. Int. 121: 47-56 (2001).
21. M. Wikström, P. Holmgren, and J. Ahlner. A2 (N-Benzylpiperazine) a new drug of abuse in Sweden. J. Anal. Toxicol. 28: 67-70 (2004).
22. S.C. Bishop, B.R. McCord, S.R. Gratz, J.R. Loeliger, and M.R. Witkowski. Simultaneous separation of different types of amphetamine and piperazine designer drugs by capillary electrophoresis with a chiral selector. J. Forensic Sci. 50(2): 1-10 (2005).
23. U.S. Drug Enforcement Administration-Department of Justice. Schedules of controlled substances: temporary placement of benzylpiperazine and trifluoromethylphenylpiperazine into Schedule I. Fed. Regist. 67: 59161-59162 (2002).
24. U.S. Drug Enforcement Administration-Department of Justice. Schedules of controlled substances. Placement of 2,5-dimethoxy-4-(n)-propylthiophenethylamine and N-benzylpiperazine into Schedule I of the Controlled Substances Act. Fed. Regist. 69: 12794-12797(2004).
25. C. Bye, A.D. Munro-Faure, A.W. Peck, and P.A. Young. A comparison of the effects of 1 -benzylpiperazine and dexamphetamine on human performance tests. Eur. j. Clin. Pharmacol. 6(3): 163-169(1973).
26. H. Campbell, W. Cline, M. Evans, J. Lloyd, and A.W. Peck. A comparison of the effects of dexamphetamine and 1 -benzylpiperazine in former addicts. Eur.J. Clin. Pharmacol. 6(3): 170-176 (1973).
27. M.H. Baumann, R.D. Clark, A.G. Budzynski, J.S. Partilla, B.E. Blough, and R.B. Rothman. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylene-dioxymethamphetamine (MDMA, or 'Ecstasy'). Neuropsychopharm. 30: 550-560 (2005).
28. HI. Yarosh, E.B. Katz, A. Coop, and W.E. Fantegrossi. MDMA-like behavioral effects of N-substituted piperazines in the mouse. Pharmacol. Biochem. Behav. 88(1): 18-27 (2007).
29. K. Tekes, L. Tóthfalusi, B. Malomvölgyi, F. Hermán, and K. Magyar. Studies on the biochemical mode of action of EGYT-475, a new antidepressant. Pol. J. Pharmacol. Pharm. 39(2): 203-211 (1987).
30. R. Lyon, M. Titeler, J. McKenney, P. Magee, and R. Glennon. Synthesis and evaluation of phenyl- and benzylpiperazines as potential serotonergic agents. ). Med. Chem. 29(5): 630-634 (1986).
31. P. Gee, S. Richardson, W. Woltersdorf, and G. Moore. Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch, New Zealand. N. Z. Med. J. 118(1227): U1784 (2005).
32. R.F. Staack, G. Fritschi, and H.M. Maurer. Studies on metabolism and toxicological detection of the new designer drug N-benzylpiperazine in urine using gas chromatography-mass spectrometry. J. Chromatogr. B 773: 35-46 (2002).
33. M.D. Schechter. Use of TFMPP stimulus properties as a model of 5-HT1 B receptor activation. Pharmacol. Biochem. Behav. 31 (1): 53-57(1988).
34. R.A. Glennon, M.E. Pierson, and J.D. McKenney. Stimulus generalization of 1-(3-trifluoromethylphenyl)piperazine (TFMPP) to propranolol, pindolol, and mesulergine. Pharmacol. Biochem. Behav. 29: 197-199 (1988).
35. J.L. Herndon, M.E. Pierson, and R.A. Glennon. Mechanistic investigation of the stimulus properties of 1 -(3-trifluoromethylphenyl)piperazine. Pharmacol. Biochem. Behav. 43: 739-748 (1992).
36. M. Baumann, R. Clark, A. Budzynski, J. Partilla, B. Blough, and R. Rothman. Effects of "Legal X" piperazine analogs on dopamine and serotonin release in rat brain. Ann. N. Y. Acad. Sci. 1025: 189-197(2004).
37. R.F. Staack, F. Fritschi, and H.M. Maurer. New designer drug 1 -(3-trifluoromethylphenyl)piperazine (TFMPP): gas chromatography/mass spectrometry and liquid chromatography/mass spectrometry studies on its phase I and II metabolism and on its toxicological detection in rat urine. J. Mass Spectrom. 38: 971-981 (2003).
38. F.T. Peters, S. Schaefer, R.F. Staack, T. Kraemer, and H.M. Maurer. Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry. J. Mass Spectrom. 38: 659-676 (2003).
39. H. Tsutsumi, M. Katagi, A. Miki, N. Shima, T. Kamata, M. Nishikawa, K. Nakajima, and H. Tsuchihashi. Development of simultaneous gas chromatography-mass spectrometric and liquid chromatography-electrospray ionization mass spectrometric determination method for the new designer drugs, N-benzylpiperazine (BZP), 1 -(3-trifluoromethylphenyl)piperazine (TFMPP) and their main metabolites in urine. J. Chromatogr. B 819: 315-322 (2005).
40. H. Tsutsumi, M. Katagi, A. Miki, N. Shima, T. Kamata, K. Nakajima, H. Inoue, T. Kishi, and H. Tsuchihashi. Metabolism and the urinary excretion profile of the recently scheduled designer drug N-benzylpiperazine (BZP) in the rat. J. Anal. Toxicol. 30: 38-43 (2006).